局部晚期胰腺腺癌立体定向在线自适应磁共振引导放疗(SMART)中急性和晚期胃肠道毒性的剂量学预测因素
本回顾性研究纳入2018至2021年在本机构接受立体定向磁共振引导在线自适应放疗(SMART)的147例局部晚期胰腺癌患者,评估剂量学预测因素与胃肠道毒性。18例发生≥2级胃肠道毒性,十二指肠V33Gy(每cc OR 1.69,95%CI 1.14-2.88)和小肠V33Gy(每cc OR 1.60,95%CI 1.01-2.53)是最显著预测因素,AUC均为0.72。作者结论认为V33Gy阈值与≥2级毒性相关,可用于指导未来上腹部SBRT的剂量体积约束。
要点
- 147例接受SMART的局部晚期胰腺癌患者中18例发生≥2级胃肠道毒性。
- 十二指肠V33Gy每cc OR 1.69(95%CI 1.14-2.88),为最显著预测因素。
- 小肠V33Gy每cc OR 1.60(95%CI 1.01-2.53),AUC均为0.72。
核心结论
- 对于接受SMART的局部晚期胰腺癌,十二指肠和小肠的V33Gy剂量体积阈值与≥2级毒性相关。
- 这些指标可用于指导未来上腹部SBRT患者的剂量体积约束。
研究设计与样本
- 回顾性评估2018至2021年在本机构接受SMART的147例局部晚期胰腺癌患者的剂量学预测因素和剂量体积数据。
- 采用CTCAE V5.0评估放疗相关急性(≤3个月)和晚期(>3个月)毒性。
- 每个危及器官匹配至≥2级毒性终点复合组,采用最小绝对收缩选择算子回归模型处理危及器官多重共线性。
- 对显著毒性组的组合平均值进行受试者工作特征曲线分析,以确定各剂量水平的关键体积。
主要发现
- 147例患者中18例发生≥2级胃肠道毒性。
- 观察到17例≥2级十二指肠毒性,最显著预测因素为V33Gy每cc OR 1.69(95%CI 1.14-2.88)。
- 观察到17例≥2级小肠毒性,最显著预测因素为V33Gy每cc OR 1.60(95%CI 1.01-2.53)。
- 十二指肠和小肠的AUC均为0.72。
- 未发现胃或大肠剂量毒性预测因素。
关键数值与推荐
- 十二指肠最佳截断点为1.00 cc(真阳性17.8%;真阴性94.9%)。
- 小肠最佳截断点为1.75 cc(真阳性16.7%;真阴性94.3%)。
- 十二指肠V33Gy每cc OR 1.69(95%CI 1.14-2.88)。
- 小肠V33Gy每cc OR 1.60(95%CI 1.01-2.53)。
临床怎么用
- 原文结论指出,十二指肠和小肠的V33Gy剂量体积阈值与≥2级毒性相关,这些指标可用于指导未来上腹部SBRT患者的剂量体积约束。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: A retrospective evaluation of dosimetric predictors and leveraged dose-volume data for gastrointestinal (GI) toxicities for locally-advanced pancreatic cancer (LAPC) treated with daily stereotactic MRI-guided online-adaptive radiotherapy (SMART). MATERIALS AND METHODS: 147 patients with LAPC were treated with SMART at our institution between 2018 and 2021. Patients were evaluated using CTCAE V5.0 for RT-related acute (≤3 months) and late (>3 months) toxicities. Each organ at risk (OAR) was matched to a ≥ grade 2 (Gr2+) toxicity endpoint composite group. A least absolute shrinkage selector operator regression model was constructed by dose-volumes per OAR to account for OAR multicollinearity. A receiver operator curve (ROC) analysis was performed for the combined averages of significant toxicity groups to identify critical volumes per dose levels. RESULTS: 18 of 147 patients experienced Gr2+ GI toxicity. 17 Gr2+ duodenal toxicities were seen; the most significant predictor was a V33Gy odds ratio (OR) of 1.69 per cc (95 % CI 1.14-2.88). 17 Gr2+ small bowel (SB) toxicities were seen; the most significant predictor was a V33Gy OR of 1.60 per cc (95 % CI 1.01-2.53). The AUC was 0.72 for duodenum and SB. The optimal duodenal cut-point was 1.00 cc (true positive (TP): 17.8 %; true negative (TN); 94.9 %). The SB cut-point was 1.75 cc (TP: 16.7 %; TN: 94.3 %). No stomach or large bowel dose toxicity predictors were identified. CONCLUSIONS: For LAPC treated with SMART, the dose-volume threshold of V33Gy for duodenum and SB was associated with Gr2+ toxicities. These metrics can be utilized to guide future dose-volume constraints for patients undergoing upper abdominal SBRT.
引用
- D'Souza A, Stowe HB, Green OL, et al. Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma. Radiother Oncol. 2024. PMID: 39137832. doi:10.1016/j.radonc.2024.110473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。